Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 640,000 ordinary shares of 25 pence each.
- Purchase Date: May 2, 2006.
- Purchase Price: 1,550.8221 pence per share.
- Treasury Holdings Post-Transaction: 158,474,678 shares.
- Shares in Issue (Excluding Treasury): 5,817,804,364 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 640,000 shares to be held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 640,000 shares by the price of 1,550.8221 pence.
- Confirm the updated total share capital structure (5,817,804,364 shares in issue plus 158,474,678 treasury shares).
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) and capital allocation strategy.